Articles from Ipsen and GENFIT

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

Regulatory News:

By Ipsen and GENFIT · Via Business Wire · December 17, 2021